SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

BACKGROUND: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial. METHODS: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Fang, Zhou, Yanwen, Zhou, Zhiguo, Ye, Fei, Huang, Baoying, Huang, Yaxiong, Ma, Jing, Zuo, Qi, Tan, Xin, Xie, Jun, Niu, Peihua, Wang, Wenlong, Xu, Yun, Peng, Feng, Zhou, Ning, Cai, Chunlin, Tang, Wei, Xiao, Xinqiang, Li, Yi, Zhou, Zhiguang, Jiang, Yongfang, Xie, Yuanlin, Tan, Wenjie, Gong, Guozhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397938/
https://www.ncbi.nlm.nih.gov/pubmed/32758689
http://dx.doi.org/10.1016/j.ijid.2020.07.053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397938/
https://www.ncbi.nlm.nih.gov/pubmed/32758689
http://dx.doi.org/10.1016/j.ijid.2020.07.053

Ejemplares similares